{"id":"fluoropyrimidine-and-platinum-containing-therapy","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Fluoropyrimidines, such as 5-fluorouracil, inhibit thymidylate synthase, disrupting DNA synthesis. Platinum-containing compounds, like cisplatin, form platinum-DNA adducts, causing DNA damage and triggering apoptosis.","oneSentence":"Fluoropyrimidine- and Platinum-containing Therapy works by interfering with DNA replication and transcription, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:00:30.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"}]},"trialDetails":[{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06251973","phase":"PHASE2","title":"A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-02-01","conditions":"Metastatic Esophageal Carcinoma, Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer","enrollment":37},{"nctId":"NCT06841679","phase":"PHASE2, PHASE3","title":"Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Beijing Biostar Pharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":778},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT02065765","phase":"","title":"International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Eli Lilly and Company","startDate":"","conditions":"Metastatic Gastric Cancer, Metastatic Adenocarcinoma of the Gastroesophageal Junction","enrollment":""},{"nctId":"NCT04074343","phase":"PHASE1","title":"TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2019-08-26","conditions":"Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":20},{"nctId":"NCT06097416","phase":"PHASE3","title":"Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"St. James's Hospital, Ireland","startDate":"2024-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT04168931","phase":"PHASE2","title":"Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC","status":"TERMINATED","sponsor":"AC Camargo Cancer Center","startDate":"2020-01-01","conditions":"Gastric Cancer Stage IV","enrollment":5},{"nctId":"NCT05190445","phase":"PHASE2","title":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pieris Pharmaceuticals, Inc.","startDate":"2021-11-01","conditions":"HER2-positive Gastric Cancer","enrollment":80},{"nctId":"NCT01983878","phase":"PHASE2","title":"A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-12","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT00917384","phase":"PHASE3","title":"Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-08","conditions":"Gastric Cancer, Adenocarcinoma","enrollment":355}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Fluoropyrimidine- and Platinum-containing Therapy","genericName":"Fluoropyrimidine- and Platinum-containing Therapy","companyName":"Beijing Biostar Pharmaceuticals Co., Ltd.","companyId":"beijing-biostar-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoropyrimidine- and Platinum-containing Therapy works by interfering with DNA replication and transcription, ultimately leading to cell death. Used for Metastatic colorectal cancer, Metastatic gastric cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}